Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Merck & Co. ($MRK) announced the results for the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.
The company reported that the study met its primary efficacy endpoint, showing that significantly fewer patients with undetectable CMV DNA at the start of study treatment developed clinically significant CMV infection through Week 24 post-HSCT.
Merck stock hit its 52 weeks high in its previous trading session. The stock is now 12 percent up on Year to Date basis while its 12 months gain stands at 30 percent.

Alimera Sciences Inc. ($ALIM) reported the filing of a New Drug Submission (NDS) for ILUVIEN®. The company is collaborating with Knight Therapeutics Inc. for this purpose. The drug is already approved in the US for treating diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Alimera stock is up 16 percent this year so far, while its value dropped 44 percent in the past 12 months. The company signed an agreement with Knight in July 2015 granting Knight the exclusive right to distribute ILUVIEN in Canada.

 

• Cigna ($CI) announced rejigging its enterprise leadership team. The company promoted three executives to the team. It also announced that the Chief Financial Officer Thomas McCarthy will retire this summer. He will be succeeded by Eric Palmer, who is currently chief financial officer of the company's global health, Cigna-HealthSpring, employer-based health care, group and supplemental insurance businesses.
• AbbVie Inc. ($ABBV) reported that he European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for a shorter, eight-week treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and minimal to moderate fibrosis*. VIEKIRAX + EXVIERA is currently approved in the European Union for use as a 12-week treatment for GT1b chronic HCV-infected patients without cirrhosis or with compensated cirrhosis.

• GlaxoSmithKline ($GSK) announced positive results from a non-inferiority lung function study. The results demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, from the twice-daily Seretide® Accuhaler® (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function. The incidences of on-treatment serious adverse events and adverse events of special interest were consistent with the known safety profile of FF/VI, established in asthma patients from other studies.
• Intersect ENT ($XENT) reported that its PROPEL Contour steroid-releasing sinus implant has been approved by the FDA. The device is used to treat chronic sinusitis and patients undergoing ethmoid, frontal or maxillary surgeries. Intersect expects to launch the product in the second quarter of the year. It reiterated its revenue guidance for the year in the range of $87 million to $89 million.

 
• GlaxoSmithKline ($GSK) announced positive results from a non-inferiority lung function study. The results demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® (fluticasone furoate/vilanterol, FF/VI) 100/25, from the twice-daily Seretide® Accuhaler® (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function. The incidences of on-treatment serious adverse events and adverse events of special interest were consistent with the known safety profile of FF/VI, established in asthma patients from other studies.
• Intersect ENT ($XENT) reported that its PROPEL Contour steroid-releasing sinus implant has been approved by the FDA. The device is used to treat chronic sinusitis and patients undergoing ethmoid, frontal or maxillary surgeries. Intersect expects to launch the product in the second quarter of the year. It reiterated its revenue guidance for the year in the range of $87 million to $89 million.

 
• Horizon Pharmaceuticals plc ($HZNP) announced the net sales of $310.3 million for the fourth quarter of the year, up 27 percent. Its quarterly net loss stood at $130.5 million while adjusted EBITDA was reported at $136.4 million. The company expects its full year 2017 net sales to be in the range of $1.24 billion to $1.29 billion, up 19 to 23 percent. Full-year 2017 adjusted EBITDA guidance stood at $525 million to $575 million, representing year-over-year growth of 12 to 22 percent and approximately 43.5 percent of sales.
• Halyard Health Inc. ($HYH) announced that its fourth quarter net sales stood at $410 million, a 2 percent increase compared to the prior year. Its net income for the fourth quarter 2016 was $10 million compared to net income of $15 million in the fourth quarter of 2015. Fourth quarter adjusted net income was $24 million compared to adjusted net income of $27 million in the prior year. The full year sales stood at $1.6 billion while the net income for the same period was reported at $40 million.

Brokerage Action Company Rating Price Target
Mizuho Raises Target Acadia Healthcare Company (ACHC)
Buy $45.00 -> $52.00
Cantor Fitzgerald Reiterates Acadia Healthcare Company (ACHC)
Neutral $45.00
FBR & Co Reiterates AVEO Pharmaceuticals (AVEO)
Outperform $3.00
Janney Montgomery Scott Reiterates Depomed (DEPO)
Buy
Mizuho Raises Target Eagle Pharmaceuticals (EGRX)
$66.00
First Analysis Downgrades HMS Holdings Corp (HMSY)
Overweight -> Equal Weight $21.00
Needham & Company LLC Initiates Heron Therapeutics (HRTX)
Buy $28.00
Evercore ISI Upgrades Illumina (ILMN)
Hold -> Buy
Avondale Partners Upgrades PRA Health Sciences (PRAH)
Underperform -> Market Perform
RBC Capital Markets Reiterates Perrigo Company plc (PRGO)
Sector Perform
Goldman Sachs Group, Inc. (The) Downgrades Smith & Nephew SNATS (SNN)
Buy -> Neutral
Robert W. Baird Downgrades TESARO (TSRO)
Outperform -> Neutral
Mizuho Raises Target Universal Health Services (UHS)
Neutral $115.00 -> $133.00

Gainers (% price change)Last TradeChangeMkt CapDigirad CorporationDRAD5.25+0.45 (9.37%)102.78MSelect Medical HldgsSEM14.15+1.15 (8.85%)1.89BIncyte CorporationINCY131.21+9.26 (7.59%)24.97BAccelerate DiagnosticsAXDX26.60+1.85 (7.47%)1.39BCodexis, Inc.CDXS4.10+0.25 (6.49%)166.84MLosers (% price change)Achillion PharmaceuticalsACHN3.86-0.38 (-8.96%)532.61MMagellan Health IncMGLN74.35-5.75 (-7.18%)1.75BCyberOptics CorporationCYBE34.15-2.25 (-6.18%)225.14MInsys Therapeutics IncINSY12.03-0.77 (-6.02%)819.84MHerbalife Ltd.HLF56.72-2.69 (-4.53%)5.16BMost Actives (dollar volume)Johnson & JohnsonJNJ122.73+1.05 (0.86%)339.98BIncyte CorporationINCY131.21+9.26 (7.59%)24.97BPfizer Inc.PFE34.26+0.20 (0.59%)210.81BBristol-Myers Squibb CoBMY56.44+0.68 (1.22%)95.04BMerck & Co., Inc.MRK66.16+0.30 (0.46%)183.98B